<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00421486</url>
  </required_header>
  <id_info>
    <org_study_id>01 KI 0501</org_study_id>
    <nct_id>NCT00421486</nct_id>
  </id_info>
  <brief_title>Oral Human Papillomavirus Infection in HIV-infected Men</brief_title>
  <official_title>Incidence, Prevalence, Spectrum of HPV-types, and Viral Load Determination of High-risk Human Papillomavirus Infection of the Oral Cavity in HIV-infected Men Who Have Sex With Men</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Deutsche Luft und Raumfahrt</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Deutsche Luft und Raumfahrt</source>
  <brief_summary>
    <textblock>
      Human papillomavirus (HPV)-infection belong to the most common sexually transmitted diseases
      worldwide. HIV-infected men having sex with men /MSM) are strongly associated with a higher
      prevalence of genitoanal HPV-infection, and perianal HPV-infections have been detected in up
      to 90% of HIV-positive men. The data concerning the incidence of oral HPV-infection in
      HIV-positive men, especially in the era of highly antiretroviral therapy, are conflicting.
      Thus, this prospective study mainly focuses on the incidence and prevalence of oral
      HPV-infection, spectrum of HPV-types, and oral high-risk HPV viral load in HIV-positive men.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Human papillomavirus (HPV)-infection belong to the most common sexually transmitted diseases
      worldwide. Estimated prevalences of subclinical genital HPV-infection in the immunocompetent
      sexually active population range from 10 to above 50%. Genetic or iatrogenic
      immunosuppression is known to play a decisive role in the initiation of a variety of
      cutaneous neoplasias and their precursor lesions. In this context, HPV-associated anogenital
      malignancies occur with high frequency in patients with HIV-infection. In several studies,
      perianal HPV-infections have been detected in up to 90% of HIV-positive men and a high
      incidence of anal dysplasia has been reported in these patients. The data concerning the
      incidence of oral HPV-infection in HIV-positive men, especially in the era of highly
      antiretroviral therapy, are conflicting. Thus, this prospective study mainly focuses on the
      incidence and prevalence of oral HPV-infection, spectrum of HPV-types, and oral high-risk HPV
      viral load in HIV-positive men.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2006</start_date>
  <completion_date type="Anticipated">January 2018</completion_date>
  <primary_completion_date type="Anticipated">January 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Spectrum of HPV types and associated clinical lesions</measure>
    <time_frame>swabs will be obtained approximately every 6 months</time_frame>
  </primary_outcome>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Papillomavirus Infections</condition>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Oral swabs for HPV-typing and high-risk HPV-determination</intervention_name>
    <description>Oral swabs for HPV-typing and high-risk HPV-determination</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        HIV-infected men who have sex with men
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HIV-infected men who have sex with men

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alexander Kreuter, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Dermatology, Ruhr University Bochum</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Norbert Brockmeyer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Dermatology, Ruhr University Bochum</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ulrike Wieland, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institute of Virology, University of Cologne</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alexander Kreuter, MD</last_name>
    <phone>0049/234/5093439</phone>
    <email>a.kreuter@derma.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Dermatology, Ruhr University Bochum</name>
      <address>
        <city>Bochum</city>
        <state>NRW</state>
        <zip>44791</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexander Kreuter, MD</last_name>
      <phone>0049/234/5093439</phone>
      <email>a.kreuter@derma.de</email>
    </contact>
    <investigator>
      <last_name>Alexander Kreuter, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Norbert Brockmeyer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institute of Virology, University of Cologne</name>
      <address>
        <city>KÃ¶ln</city>
        <state>NRW</state>
        <zip>50935</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ulrike Wieland, MD</last_name>
    </contact>
    <investigator>
      <last_name>Ulrike Wieland, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.kompetenznetz-hiv.de</url>
    <description>Deutsches Kompetenznetz HIV/AIDS</description>
  </link>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 10, 2007</study_first_submitted>
  <study_first_submitted_qc>January 11, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 12, 2007</study_first_posted>
  <last_update_submitted>January 20, 2016</last_update_submitted>
  <last_update_submitted_qc>January 20, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 21, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Deutsche Luft und Raumfahrt</investigator_affiliation>
    <investigator_full_name>Alexander Kreuter</investigator_full_name>
    <investigator_title>Prof. Dr.</investigator_title>
  </responsible_party>
  <keyword>Oral human papillomavirus infection</keyword>
  <keyword>HIV-infection</keyword>
  <keyword>High-risk HPV viral load</keyword>
  <keyword>Oral human papillomavirus infection in HIV-positive men</keyword>
  <keyword>Treatment Experienced</keyword>
  <keyword>Treatment Naive</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Papillomavirus Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

